Y. Allory

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.

The paper develops patient-derived xenografts (PDXs) for bladder and ureteral cancers, identifies molecular subtypes, and shows that combined FGFR/EGFR inhibition is more effective than single-agent therapy for FGFR3-mutant tumors.

Epigenomic mapping identifies a super-enhancer repertoire that regulates cell identity in bladder cancers through distinct transcription factor networks

The paper identifies super-enhancer networks regulating bladder cancer subtypes through transcription factors, showing their role in cell identity and inflammatory response suppression.

FGFR3 activating mutations induce luminal-like papillary bladder tumor formation and favor a male gender bias.

This study shows FGFR3-S249C mutations drive luminal-like papillary bladder tumors in mice and correlate with male gender bias and AR activity in human tumors.

PPARG is a tumor suppressor in basal bladder tumors offering new potential therapeutic opportunities.

The paper identifies PPARγ as a tumor suppressor in basal bladder tumors and suggests therapeutic opportunities through PPARγ activation.

A consensus molecular classification of muscle-invasive bladder cancer

The paper identifies six consensus molecular classes of muscle-invasive bladder cancer using transcriptomic data and classification systems, providing a framework for future biomarker validation.